Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate Improvement of Symptoms of RLS in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms Who Take OXN PR Compared to Subjects Taking Placebo (PLA).

NCT01112644 is registered in ClinicalTrials.gov with Mundipharma Research GmbH & Co KG as lead sponsor.

NCT NCT01112644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01112644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate Improvement of Symptoms of RLS in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms Who Take OXN PR Compared to Subjects Taking Placebo (PLA).
Lead sponsor
Mundipharma Research GmbH & Co KG
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2010
Completion date
June 30, 2011
Enrollment
205 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe idiopathic rls with daytime symptoms